Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study
Authors:
- Koji IinumaKIKoji Iinuma
- Koji KameyamaKKKoji Kameyama
- Tomoki TaniguchiTTTomoki Taniguchi
- Kei KawadaKKKei Kawada
- Takashi IshidaTITakashi Ishida
- Kimiaki TakagiKTKimiaki Takagi
- Shingo NagaiSNShingo Nagai
- Torai EnomotoTETorai Enomoto
- Masayuki TomiokaMTMasayuki Tomioka
- Makoto KawaseMKMakoto Kawase
- Shinichi TakeuchiSTShinichi Takeuchi
- Daiki KatoDKDaiki Kato
Open Access
Abstract
This study aimed to evaluate the effectiveness and safety of molecular-targeted therapies (MTTs) after the discontinuation of nivolumab and ipilimumab (NIVO+IPI) combination therapy in patients who had been diagnosed with advanced/metastatic renal cell carcinoma as real-world outcomes. We enrolled patients treated with MTTs following initial therapy with NIVO+IPI at nine institutions in Japan. We evaluated the objective response rate (ORR) as the primary endpoint and disease control rate (DCR), best overall response, and oncological outcomes (overall survival (OS) and progression-free survival (PFS)) as the secondary endpoints. We also evaluated factors predictive of disease progression after the administration of MTTs. Patients were followed up for a median of 8 months. The ORR was 44.8%, and the DCR was 72.4%. The median OS and PFS of MTTs after NIVO+IPI were 18 months and 8 months, respectively. A total of 31% of patients experienced grade 3/4 MTT-related adverse events. The median PFS in patients with bone metastases was significantly shorter than that in those without bone metastases (4 vs. 12 months, p = 0.012). MTTs may be a useful secondary treatment option after the discontinuation of NIVO+IPI.Keywords
This publication has 25 references indexed in Scilit:
- Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinomaEuropean Journal of Cancer, 2019
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Systemic Therapy for Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2017
- Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinomaAnnals of Oncology, 2016
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyThe Lancet Oncology, 2013
- Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinibAnnals of Oncology, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-upCancer Research, 2006
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982